Injection of embryonic median ganglionic eminence cells or fibroblasts within the amygdala in rats kindled from the piriform cortex

Gallego, José María; Sancho, Ferrán; Vidueira, Sandra; Ortíz, Laura Velasco; Gómez‐Pinedo, Ulises; Barcia, Juan A.

doi:10.1016/j.seizure.2010.06.001

Cited by 10 publications

(8 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study in a rat model of kindling epilepsy also showed the efficiency of rat MGE cells for reducing seizures (Gallego et al, 2010, Table 1). Grafting E14.5 rat MGE into the amygdala following 3 days of full kindling increased thresholds for after discharges and seizures at 3–24 days post-grafting, in comparison to kindled rats receiving fibroblasts.…”

Section: Efficacy Of Primary Gaba-ergic Cell Grafts For Mediating mentioning

confidence: 94%

GABA-ergic cell therapy for epilepsy: Advances, limitations and challenges

Shetty

Upadhya²

2016

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

Diminution in the number of gamma-amino butyric acid positive (GABA-ergic) interneurons and their axon terminals, and/or alterations in functional inhibition are conspicuous brain alterations believed to contribute to the persistence of seizures in acquired epilepsies such as temporal lobe epilepsy. This has steered a perception that replacement of lost GABA-ergic interneurons would improve inhibitory synaptic neurotransmission in the epileptic brain region and thereby reduce the occurrence of seizures. Indeed, studies using animal prototypes have reported that grafting of GABA-ergic progenitors derived from multiple sources into epileptic regions can reduce seizures. This review deliberates recent advances, limitations and challenges concerning the development of GABA-ergic cell therapy for epilepsy. The efficacy and limitations of grafts of primary GABA-ergic progenitors from the embryonic lateral ganglionic eminence and medial ganglionic eminence (MGE), neural stem/progenitor cells expanded from MGE, and MGE-like progenitors generated from human pluripotent stem cells for alleviating seizures and co-morbidities of epilepsy are conferred. Additional studies required for possible clinical application of GABA-ergic cell therapy for epilepsy are also summarized.

show abstract

Section: Efficacy Of Primary Gaba-ergic Cell Grafts For Mediating mentioning

confidence: 94%

GABA-ergic cell therapy for epilepsy: Advances, limitations and challenges

Shetty

Upadhya²

2016

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

show abstract

“…Several evidences indicate that therapeutic benefits can be obtained by transplanting fetal GABAergic progenitors into the dentate gyrus in rodents with TLE. Recent progress in cell transplantation using the TLE model were well described (76) and, fetal hippocampal cell grafts, neuronal precursor cells from medial ganglionic eminence, and other neural stem cells (NSCs) have been tested as efficacious transplantable cells able to replace damaged hippocampal neurons in epilepsy models (77,78).…”

Section: Stem-cell Therapy And/or Neurotrophic Factors As Inducers Ofmentioning

confidence: 99%

ABC-transporters as stem-cell markers in brain dysplasia/tumor epilepsies

Czornyj

Lazarowski

2014

Front Biosci

View full text Add to dashboard Cite

ABC-transporters prevent the access of antiepileptic drugs into brain parenchyma, which partly explains why seizures are frequently refractory to AEDs treatment. Overexpression of ABC-transporters and stem-cell markers including CD34, have been detected in malformations of cortical development (MCD) and brain tumors. ABC-transporters are constitutively expressed during maturation of normal progenitor stem-cells and cancer stem-cells. These abnormal/immature cells of MCD or brain tumors play an active role in the epileptogenesis but the precise nature of this phenomenon is unclear. Irrespective of their property in the pharmacoresistance, ABCB1-transporter P-glycoprotein also plays a role in the membrane depolarization, suggesting that constitutive P-glycprotein overexpression in MCD and brain tumors could explain their epileptogeneic properties. MCD as wells as brain tumors arise from abnormal progenitor cells, where ABC-t together with others stem cell markers, could help to better identification of these abnormal progenitor cells and serve as biomarker of risk for seizure relapse after epilepsy surgery.

show abstract

“…As shown in Table 1 , a variety of cell types have been tested in animal models of epilepsy, including neural stem cells; human induced pluripotent stem cells; GABAergic progenitors derived from mouse or human embryonic stem cells; GABAergic precursors; striatal precursor cells (Hattiangady et al, 2008 ; Baraban et al, 2009 ; Gallego et al, 2010 ; De la Cruz et al, 2011 ; Shetty and Upadhya, 2016 ). Several studies now convincingly support the notion that some types of cells can successfully treat epilepsy in animal models.…”

Section: Cell Therapy Approaches: Direct Cell Graft Injectionmentioning

confidence: 99%

New Tools for Epilepsy Therapy

Falcicchia

Simonato

Verlengia

2018

Front. Cell. Neurosci.

View full text Add to dashboard Cite

One third of the epilepsies are refractory to conventional antiepileptic drugs (AEDs) and, therefore, identification of new therapies is highly needed. Here, we briefly describe two approaches, direct cell grafting and gene therapy, that may represent alternatives to conventional drugs for the treatment of focal epilepsies. In addition, we discuss more in detail some new tools, cell based-biodelivery systems (encapsulated cell biodelivery (ECB) devices) and new generation gene therapy vectors, which may help in the progress toward clinical translation. The field is advancing rapidly, and there is optimism that cell and/or gene therapy strategies will soon be ready for testing in drug-resistant epileptic patients.

show abstract

Injection of embryonic median ganglionic eminence cells or fibroblasts within the amygdala in rats kindled from the piriform cortex

Abstract: MGE cells implanted at the amygdala may control the focal component of temporolimbic seizures. This effect may be mediated by local release of GABA.

Cited by 10 publications

References 13 publications

GABA-ergic cell therapy for epilepsy: Advances, limitations and challenges

GABA-ergic cell therapy for epilepsy: Advances, limitations and challenges

ABC-transporters as stem-cell markers in brain dysplasia/tumor epilepsies

New Tools for Epilepsy Therapy

Contact Info

Product

Resources

About